189 related articles for article (PubMed ID: 15449964)
1. Comparisons of hypertension-related costs from multinational clinical studies.
Mullins CD; Sikirica M; Seneviratne V; Ahn J; Akhras KS
Pharmacoeconomics; 2004; 22(15):1001-14. PubMed ID: 15449964
[TBL] [Abstract][Full Text] [Related]
2. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Financial and health costs of uncontrolled blood pressure in the United Kingdom.
Lloyd A; Schmieder C; Marchant N
Pharmacoeconomics; 2003; 21 Suppl 1():33-41. PubMed ID: 12648033
[TBL] [Abstract][Full Text] [Related]
5. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
6. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Croom KF; Plosker GL
Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
[TBL] [Abstract][Full Text] [Related]
7. Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories.
Schreyögg J; Tiemann O; Stargardt T; Busse R
Health Econ; 2008 Jan; 17(1 Suppl):S95-103. PubMed ID: 18186031
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial.
Reed SD; Friedman JY; Gnanasakthy A; Schulman KA
Int J Technol Assess Health Care; 2003; 19(2):396-406. PubMed ID: 12862196
[TBL] [Abstract][Full Text] [Related]
9. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
10. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
11. Resource costing for multinational neurologic clinical trials: methods and results.
Schulman K; Burke J; Drummond M; Davies L; Carlsson P; Gruger J; Harris A; Lucioni C; Gisbert R; Llana T; Tom E; Bloom B; Willke R; Glick H
Health Econ; 1998 Nov; 7(7):629-38. PubMed ID: 9845256
[TBL] [Abstract][Full Text] [Related]
12. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
[TBL] [Abstract][Full Text] [Related]
13. The cost of schizophrenia: lessons from an international comparison.
Blomqvist AG; Léger PT; Hoch JS
J Ment Health Policy Econ; 2006 Dec; 9(4):177-83. PubMed ID: 17200594
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Exercise-Based Cardiac Rehabilitation Programs for Chronic Heart Failure Patients in Colombia.
Rincón M; Rojas MX; Rodriguez Romero VA; Tamayo DC; Franco C; Castro H; Brophy J; Dennis R
J Cardiopulm Rehabil Prev; 2016; 36(1):12-9. PubMed ID: 26702862
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
Plosker GL; Keam SJ
Pharmacoeconomics; 2006; 24(12):1249-72. PubMed ID: 17129078
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of supervised exercise therapy in heart failure patients.
Kühr EM; Ribeiro RA; Rohde LE; Polanczyk CA
Value Health; 2011; 14(5 Suppl 1):S100-7. PubMed ID: 21839879
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective.
Szucs TD; Waeber B; Tomonaga Y
J Hum Hypertens; 2010 Feb; 24(2):117-23. PubMed ID: 19536166
[TBL] [Abstract][Full Text] [Related]
18. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.
Kauf TL; Velazquez EJ; Crosslin DR; Weaver WD; Diaz R; Granger CB; McMurray JJ; Rouleau JL; Aylward PE; White HD; Califf RM; Schulman KA
Am Heart J; 2006 Jan; 151(1):206-12. PubMed ID: 16368320
[TBL] [Abstract][Full Text] [Related]
19. Depression: cost-of-illness studies in the international literature, a review.
Berto P; D'Ilario D; Ruffo P; Di Virgilio R; Rizzo F
J Ment Health Policy Econ; 2000 Mar; 3(1):3-10. PubMed ID: 11967432
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
